The latest trading session saw Amgen (AMGN) ending at $275.36, denoting a +0.59% adjustment from its last day's close. The stock's performance was ahead of the S&P 500's daily loss of 0.11%. On the other hand, the Dow registered a gain of 0.12%, and the technology-centric Nasdaq decreased by 0.41%.

The world's largest biotech drugmaker's stock has dropped by 5.97% in the past month, falling short of the Medical sector's gain of 3.03% and the S&P 500's gain of 2.7%.

The investment community will be paying close attention to the earnings performance of Amgen in its upcoming release. It is anticipated that the company will report an EPS of $3.83, marking a 3.77% fall compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $7.45 billion, showing a 21.98% escalation compared to the year-ago quarter.

AMGN's full-year Zacks Consensus Estimates are calling for earnings of $19.48 per share and revenue of $32.91 billion. These results would represent year-over-year changes of +4.45% and +16.75%, respectively.

Investors should also pay attention to any latest changes in analyst estimates for Amgen. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.08% lower. Amgen is currently sporting a Zacks Rank of #3 (Hold).

In terms of valuation, Amgen is presently being traded at a Forward P/E ratio of 14.05. Its industry sports an average Forward P/E of 23.73, so one might conclude that Amgen is trading at a discount comparatively.

Also, we should mention that AMGN has a PEG ratio of 2.57. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.61 based on yesterday's closing prices.